Patient-Focused Integrated Solution
With our patented SynerFuse® e-TLIF™ procedure we hope to help people live without pain by making traditional spine implant surgery more successful and cost effective by combining neuromodulation at the time surgeons are performing fusion back surgery.

Reducing Clinical Risk and Technical Risk Early with the Completion of the First-in-Human Study
SynerFuse® is gathering safety, efficacy, and cost-effectiveness data in a first-in-human study to reduce clinical and technical risk in a fraction of the time of conventional Class III medical device start-ups.

Our Technology
The SynerFuse® NeuroFuse® e-TLIF™ System incorporates input from the company’s strategic medical advisors and learnings from our completed proof-of-concept (POC) study. The major components of the device include an implantable programmable generator (“IPG”), a multi-channel lead to deliver electrical impulses from the IPG to the spine, and a mobile device application to enable individualized programming of the IPG.

 Strategic Partnerships to Reduce Capital Requirement, Improve Time to Market and Increase Innovation
Strategic partnerships that bring together the necessary technical skills and technological innovations will enable SynerFuse® to reduce R&D time by up to 75% and reduce capital needs by up to 80% over comparable startups.

Broad Patent Coverage to Enable Novel Innovation
SynerFuse® has 11 patents issued including the United States, Canada, and Australia. The SynerFuse® IP strategy protects key aspects of our concept and technology across the globe to enable our novel approach to solving chronic back pain.